KRAS and neoplasm: The TME, composed of stromal and immune cell populations, plays a critical role in modulating tumour aggressiveness and treatment response to therapeutic agents such as KRAS inhibitors and immunotherapies,45 thereby limiting the clinical translatability of TME‐exclusive predictive models.